Skip to main content

Table 1 Table 1

From: Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study

 

T2DM Carvedilol

(N = 9)

T2DM Metoprolol

(N = 10)

Healthy controls

(N = 10)

P Carvedilol vs. metoprolol

P Carvedilol vs. control

P Metoprolol vs. control

Age (years)

58.9 ± 2.67

58.0 ± 3.02

47.6 ± 1.89

0.83

0.003

0.009

Sex (M/F)

7/2

9/1

5/5

   

Smoking (%)

1 (11)

2 (20)

0

   

Oral hypoglycaemic* (%)

8 (89)

9 (90)

0

   

Aspirin (%)

0

0

0

   

Statins (%)

3 (33)

5 (50)

0

   

ACE inhibitors/AT2 B (%)

4 (44)

3 (30)

0

   

Body weight (kg)

89.72 ± 7.10

97.9 ± 5.76

75.62 ± 4.24

0.38

0.10

0.006

BMI (Kg/m²)

29.26 ± 1.76

32.22 ± 1.84

24.4 ± 0.93

0.27

0.02

0.002

Systolic BP (mm Hg)

142.4 ± 5.09

143.4 ± 5.12

 

0.90

  

Diastolic BP (mm Hg)

71.4 ± 2.59

70.5 ± 4.67

 

0.87

  

Heart rate (beats/min)

67.1 ± 2.16

69.4 ± 3.31

 

0.58

  

Fasting glucose (mmol/L)

8.76 ± 0.78

8.54 ± 1.11

5.2 ± 0.17

   

Fasting insulin (μU/l)

10.20 ± 3.20

10.82 ± 2.14

    

Hb A1c (%)

7.6 ± 0.59

7.29 ± 0.42

5.24 ± 0.10

0.67

0.0004

0.0002

Total Cholesterol (mmol/L)

4.12 ± 0.28

3.93 ± 0.25

4.5 ± 0.29

0.62

0.36

0.15

LDL (mmol/L)

2.29 ± 0.31

2.25 ± 0.27

2.70 ± 0.26

0.93

0.29

0.22

HDL (mmol/L)

1.19 ± 0.06

1.09 ± 0.10

1.40 ± 0.14

0.42

0.19

0.09

TG (mmol/L)

1.41 ± 0.27

1.33 ± 0.26

0.90 ± 0.17

0.83

0.12

0.18

CRP (mmol/L)

3.00 ± 0.44

6.80 ± 2.38

2.00 ± 0.58

0.15

0.10

0.05

  1. * Oral hypoglycaemic: Included patients taking both metformin and sulfonylurea
  2. Abbreviations:T2DM: Patients with Type 2 Diabetes; M/F: Male/Female; ACE inhibitors: Angiotensin Converting Enzyme inhibitors; AT2B: Angiotensin 2 Blockers; BMI: Body Mass Index, BP: Blood Pressure; Hb A1c: Glycosylated Hemoglobin A1c; LDL: Low Density Lipoprotein; HDL: High Density Lipoprotein; TG: TriGlyceride; CRP: C-Reactive Protein.